LEADER 03906nam 2201021z- 450 001 9910346840903321 005 20231214133429.0 010 $a3-03921-192-7 035 $a(CKB)4920000000095231 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/52779 035 $a(EXLCZ)994920000000095231 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aMarine Natural Products and Obesity 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (194 p.) 311 $a3-03921-191-9 330 $aObesity and related co-morbidities are increasing worldwide and pose a serious health problem. Changes in lifestyle and diet would be the best remedies to fight obesity; however, many people will still rely on medical aid. Marine organisms have been prolific in the production of bioactive compounds for many diseases, e.g., cancer, and promise to be an excellent source for natural-derived molecules and novel nutraceuticals. Bioactive compounds with beneficial activities towards obesity have been described from diverse marine organism including marine algae, bacteria, sponges, fungi, crustaceans or fish. This Special Issue will highlight the progress in the following topics: Bioactive compounds for the treatment of obesity and obesity-related co-morbidities (diabetes, fatty liver, hyperlipidemia) from marine organisms; the isolation of novel compounds, the bioactivity screening of marine organisms and the elucidation of molecular mode of action of marine bioactive compounds. 610 $anatural compounds 610 $aanti-obesity drugs 610 $ahigh fat diet 610 $aIshige okamurae 610 $afat 610 $azebrafish Nile red fat metabolism assay 610 $aphysical exercise 610 $aJAK2-STAT3 610 $ametabolite profiling 610 $aobesity 610 $achlorophyll derivatives 610 $abrown seaweed 610 $aSkate skin 610 $aPPAR? 610 $amarine alga 610 $amarine biodiscovery 610 $askate skin 610 $alipolytic 610 $aleptin 610 $auncoupling protein 1 610 $a3T3-L1 cells 610 $aglucolipid metabolism disorder 610 $anutrition 610 $abioactivity 610 $achitosan oligosaccharide 610 $adiphlorethohydroxycarmalol (DPHC) 610 $anutraceuticals 610 $awhole small animal models 610 $ahigh-fat diet 610 $aadipocyte 610 $adyslipidemia 610 $abioactivity screening 610 $aperoxisome proliferator-activated receptor gamma 610 $awhite adipose tissue 610 $aantiobesity 610 $afatty liver disease 610 $athermal proteome profiling 610 $ainflammation 610 $acyanobacteria 610 $aRaja kenojei 610 $aArthrospira maxima 610 $acellularity 610 $aadipocytes 610 $abioactive compound 610 $acollagen peptide 610 $adouble-blind 610 $abisabolane-related compounds 610 $aproliferation 610 $afatty acid metabolism 610 $acholesterol metabolism 610 $acollagen 610 $arandomized controlled trial 610 $amechanisms of action 610 $amurine pre-adipocytes 610 $aadipogenesis 610 $afucan 610 $amarine sponges 610 $alabel-free quantitative proteomics 610 $adiabetes 610 $abody fat 700 $aVasconcelos$b Vítor$4auth$01301488 702 $aUrbatzka$b Ralph$4auth 906 $aBOOK 912 $a9910346840903321 996 $aMarine Natural Products and Obesity$93033517 997 $aUNINA